Civitas Therapeutics
CHELSEA, MA · Founded 2009 · CIK 0001509697 · Biotech · Acquired
Inhaled levodopa formulation for rapid-onset Parkinson's disease treatment
civitastx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $104M
- 3 Form D · Aug 2014
- 145 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 15 granted · 25 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201020112012201320142015
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $10,000,000 | |
| Private capital raised | Form D · SEC | $38,299,999 | |
| Private capital raised | Form D · SEC | $55,250,000 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2824 | LEAP THERAPEUTICS, INC. | — | $105M |
| 2825 | CENTRILLION BIOSCIENCES, INC. | — | — |
| 2826 | Adaptimmune | — | $104M |
| 2827 | Civitas Therapeutics | — | $104M |
| 2828 | AVATAR MEDICAL, LLC | — | — |
| 2829 | NEPHROGEN INC. | — | — |
| 2830 | JUNIPERO THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Glenn BatchelderDirector · Executive Officer
- GLENN BATCHELDERDirector
- RICHARD BATYCKYExecutive Officer
- ANDREA FRANZExecutive Officer
- MARTIN FREEDExecutive Officer
- David HirschDirector
- DAVID HIRSCHDirector
- Robert HopfnerDirector
- ROB HOPFNERDirector
- MARK IWICKIDirector · Executive Officer
- Blair JacksonDirector
- BLAIR JACKSONDirector
- Aidan KingDirector
- AIDAN KINGDirector
- TIMOTHY NELSONDirector
- ROBERT ROCHEDirector
- Robert Roche, Jr.Director
- Rajeev ShahDirector
- RAJEEV SHAHDirector
- Timothy ShannonDirector
- TIM SHANNONDirector
- BRYAN STUARTExecutive Officer
- MARY TAYLORExecutive Officer
Patents
- Devices And Methods For Puncturing A Capsule To Release A Powdered Medicament Therefromapplication
- Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)application
- Inhalable Sustained Therapeutic Formulationsapplication
- Surfactant Formulations for Inhalationapplication
- Devices And Methods For Puncturing A Capsule To Release A Powdered Medicament Therefromapplication
- Surfactant Formulations for Inhalationapplication
- Low Dose Pharmaceutical Powders for Inhalationapplication
- Triptan Powders for Pulmonary Deliveryapplication
- Surfactant Formulations For Inhalationapplication
- Dosator Apparatus for Filling a Capsule with Dry Powdergranted
- Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)application
- Devices And Methods For Puncturing A Capsule To Release A Powdered Medicament Therefromapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.